GHK-Cu: Research Overview, Mechanisms, and Current Evidence

GHK-Cu is a copper complex of the naturally occurring tripeptide glycyl-L-histidyl-L-lysine (GHK), found in human plasma, saliva, and urine, where its level is reported to decline with age. In preclinical research it has been studied as an antioxidant and tissue-repair signaling molecule, with most published work focused on skin, wound, and anti-inflammatory models. The information below summarizes published research for educational and research purposes only. It is not medical advice and is not guidance for use in humans.

ClassCopper-binding tripeptide
Also Known AsCopper peptide, GHK-Cu
SequenceGly-His-Lys with bound Cu(II)
Research FocusTissue repair, antioxidant signaling
View at Project Zero

Available for research use from our preferred vendor, Project Zero. For laboratory research use only.

How It Works (Preclinical Mechanisms)

In preclinical models, GHK-Cu has been reported to bind copper and influence signaling pathways linked to antioxidant defense, tissue remodeling, and inflammation.

  • Binds copper(II) ions and is studied as a carrier that influences copper-dependent enzymes and antioxidant pathways.
  • Reported to reduce pro-inflammatory cytokines such as TNF-alpha, IL-6, and IL-1-beta in experimental settings.
  • Investigated as a modulator of oxidative stress, increasing superoxide dismutase activity and lowering reactive oxygen species in cell and animal models.
  • Reported to bind the antioxidant enzyme peroxiredoxin 6 (PRDX6) and to support mitochondrial function in preclinical work.

Areas of Research Interest

Published studies have examined GHK-Cu in the following research contexts. Most evidence is preclinical, drawn from cell-culture and animal models.

Skin and wound research

Studied in wound-dressing and skin models for effects on collagen deposition, angiogenesis, and tissue remodeling.

Antioxidant and anti-inflammatory activity

Examined in cell and animal models for reduction of oxidative stress and inflammatory cytokines.

Lung and fibrosis models

Investigated in mouse models of silica- and bleomycin-induced lung inflammation and fibrosis.

Aging and longevity models

Studied in invertebrate models such as Caenorhabditis elegans for effects on lifespan and stress resistance.

Reported Study Parameters

For laboratory research use only. The table below reports the doses and routes used in specific published studies, with sources. It describes what researchers administered in these models and is not a protocol, recommendation, or guidance for use in humans or animals. Animal-study doses are expressed per kilogram of body weight.

Research ModelDose and Route ReportedSource
Silica-induced lung inflammation and fibrosis (mouse)2 and 20 mg/kg, intraperitoneal injectionBian 2024·DOI
Aging and stress resistance (Caenorhabditis elegans)Added to culture medium; lifespan and stress endpoints reported (concentration in source)Wen 2026·DOI
Human researchNo validated systemic regimen established; published human work centers on topical and dermatologic useOgorek 2025·DOI

Products are supplied as lyophilized powder requiring reconstitution. For reconstitution concentration math, use the Peptide Calculator.

Latest Research (2024 to 2026)

Recent peer-reviewed literature indexed on PubMed continues to characterize how GHK-Cu works in preclinical models while underscoring how limited the human evidence remains.

Aging and mitochondrial function

A 2026 study reported that GHK-Cu extended lifespan in Caenorhabditis elegans and improved resistance to oxidative and thermal stress, acting through mitochondrial support and activation of the DAF-16 and SKN-1 antioxidant pathways. PubMed·DOI

Acute inflammation (zebrafish)

A 2026 study reported that GHK-Cu reduced neutrophil and macrophage migration and lowered pro-inflammatory cytokines while raising the anti-inflammatory cytokine IL-10 in a zebrafish larvae model of chemically induced inflammation. PubMed·DOI

Lung fibrosis and PRDX6 (mouse)

A 2024 study reported that GHK-Cu attenuated lung inflammation and fibrosis in a silicosis mouse model and identified peroxiredoxin 6 (PRDX6) as a molecular binding target, with the authors noting no significant systemic toxicity at the doses tested. PubMed·DOI

Bone and vascular signaling (in vitro)

A 2025 study reported that copper complexes of GHK conjugated to hyaluronan showed antioxidant activity and promoted osteogenic and angiogenic factors such as BMP-2 and VEGF in cell-based assays. PubMed·DOI

Current state of the evidence. GHK-Cu is investigational. The bulk of the evidence is preclinical, from cell-culture and animal models, with human work focused largely on topical and cosmetic dermatology. It is not an approved drug for systemic use, and controlled human trials would be needed before conclusions about safety and efficacy could be drawn.

Research Questions

What is GHK-Cu?

GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, a molecule that occurs naturally in human plasma and other fluids and that has been studied for antioxidant and tissue-repair signaling in preclinical models.

What is the current state of human evidence?

Most human-relevant work involves topical and dermatologic formulations. There is no validated systemic regimen, and the systemic data remain preclinical.

What does the available safety literature suggest?

In a 2024 mouse study, the authors reported no significant systemic toxicity at the doses tested, but the overall human safety data set is limited and long-term systemic safety has not been established.

Referenced Citations

Literature indexed on PubMed.

  1. Wen, H., et al. (2026). The GHK-Cu delays aging in Caenorhabditis elegans via coordinated regulation of mitochondrial function and activation of DAF-16/SKN-1 pathways. Biogerontology, 27(3). PubMed·DOI
  2. Hu, J., et al. (2026). Glycyl-L-histidyl-L-lysine-Cu (GHK-Cu) attenuates CuSO4 or LPS induced-inflammation in zebrafish larvae model. Eur. J. Pharmacol., 1023, 178880. PubMed·DOI
  3. Greco, V., et al. (2025). Copper complexes with new glycyl-L-histidyl-L-lysine-hyaluronan conjugates show antioxidant properties and osteogenic and angiogenic synergistic effects. Bioconjug. Chem., 36(4), 662-675. PubMed·DOI
  4. Ogorek, K., et al. (2025). Are we ready to measure skin permeation of modern antiaging GHK-Cu tripeptide encapsulated in liposomes? Molecules, 30(1), 136. PubMed·DOI
  5. Bian, Y., et al. (2024). The glycyl-L-histidyl-L-lysine-Cu tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6. Redox Biol., 75, 103237. PubMed·DOI

PeptideInfo.org provides information strictly for educational and research purposes. All referenced products are intended for laboratory and research use only and are not approved for human consumption, medical use, or self-administration. Nothing on this page constitutes medical advice. Research summaries reference literature indexed on PubMed.

Scroll to Top